Avalo Therapeutics, INC 8-K filings

Avalo Therapeutics reported positive third quarter 2024 financial results, including a net income of $23 million, and announced the dosing of the first patient in its Phase 2 LOTUS trial for AVTX-009.

Avalo Therapeutics has initiated its Phase 2 LOTUS trial, dosing the first patient with AVTX-009 for the treatment of hidradenitis suppurativa.

Avalo Therapeutics is progressing its AVTX-009 program for Hidradenitis Suppurativa (HS), supported by clinical evidence and a cash runway extending into 2027.

Avalo Therapeutics has regained compliance with Nasdaq listing rules after its market value exceeded $35 million for ten consecutive trading days.

Avalo Therapeutics' stockholders approved amendments to the company's equity incentive and employee stock purchase plans at the annual meeting on August 13, 2024.

Avalo Therapeutics reported its second quarter 2024 financial results, highlighted by a $93.4 million cash position and the expected initiation of the Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa in the second half of 2024.

Avalo Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with listing requirements regarding minimum stockholders' equity.

Avalo Therapeutics has appointed Mittie Doyle, M.D., FACR, as its new Chief Medical Officer, effective July 15, 2024, to lead the company's clinical development efforts.

Avalo Therapeutics has announced that the Investigational New Drug (IND) application for AVTX-009, an anti-IL-1 monoclonal antibody, is now active, allowing the company to proceed with its Phase 2 clinical trial for hidradenitis suppurativa.

Avalo Therapeutics has appointed Paul Varki as its new Chief Legal Officer, bringing over 20 years of pharmaceutical industry experience to the role.

Avalo Therapeutics has filed an amendment to its previous 8-K report to restate the audited financial statements of AlmataBio and the pro forma combined financials after acquiring the company.

Avalo Therapeutics released an updated investor presentation highlighting the potential of AVTX-009, an anti-IL-1 mAb, for treating Hidradenitis Suppurativa (HS) and other autoimmune diseases.

Avalo Therapeutics has finalized its acquisition of AlmataBio, providing pro forma financial information reflecting the merger and associated PIPE financing.

Avalo Therapeutics received a notice from Nasdaq for failing to maintain the minimum stockholders' equity requirement for continued listing.

Avalo Therapeutics announced its first quarter 2024 financial results, highlighted by a significant private placement and progress towards a Phase 2 trial for AVTX-009.

Avalo Therapeutics has acquired a Phase 2 ready asset and secured up to $185 million in financing, positioning the company for future clinical trials.

Avalo Therapeutics has acquired AlmataBio, gaining a Phase 2-ready anti-IL-1 antibody and securing up to $185 million in private financing.

Avalo Therapeutics has regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split, but will be subject to a one-year monitoring period.